Ralph Riley, MD
Family Medicine · Saluda, SCNPI 1861472490
Payments from drug & device makers
Across 342 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$692
- AstraZeneca$534
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$474
- Lilly USA, LLC$428
- Boehringer Ingelheim$407
- Otsuka America Pharmaceutical, Inc.$264
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,828100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $692 |
| AstraZeneca | 32 | $534 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $474 |
| Lilly USA, LLC | 28 | $428 |
| Boehringer Ingelheim | 20 | $407 |
| Otsuka America Pharmaceutical, Inc. | 13 | $264 |
| Abbott | 13 | $250 |
| Sanofi-aventis U.S. LLC | 15 | $247 |
| AbbVie | 16 | $243 |
| Pfizer | 13 | $220 |
| Johnson & Johnson(2 entities) | 14 | $214 |
| Novartis | 12 | $197 |
| Merck | 14 | $196 |
| Dexcom, Inc. | 10 | $160 |
| GSK | 9 | $138 |
| Esperion Therapeutics, Inc. | 8 | $134 |
| Sunovion Pharmaceuticals Inc. | 8 | $126 |
| Lundbeck LLC | 7 | $126 |
| Amgen | 6 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Amarin Pharma, Inc. | 5 | $81 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Bayer | 3 | $57 |
| Stryker | 1 | $56 |
| Inspire Medical Systems, Inc. | 1 | $45 |
| Avanir Pharmaceuticals, Inc. | 2 | $43 |
| Inari Medical, Inc. | 1 | $42 |
| Cranial Technologies, Inc | 2 | $38 |
| Optinose US, Inc. | 2 | $35 |
| Edwards Lifesciences | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$153
How this compares
$5,828 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 281 | $155,666 |
| JardianceEmpagliflozin | 108 | $92,927 |
| FarxigaDapagliflozin Propanediol | 127 | $85,193 |
| TradjentaLinagliptin | 144 | $76,013 |
| EntrestoSacubitril/Valsartan | 81 | $55,374 |
| JanuviaSitagliptin Phosphate | 56 | $48,241 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $46,657 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $45,517 |
| XareltoRivaroxaban | 68 | $37,161 |
| RexultiBrexpiprazole | 33 | $36,618 |
| OzempicSemaglutide | 32 | $35,707 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $25,858 |
| LinzessLinaclotide | 32 | $21,227 |
| TrulicityDulaglutide | 21 | $21,110 |
| Divalproex Sodium | 344 | $20,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $407 | $174,685263 claims |
| PfizerEliquis | $220 | $155,666281 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $534 | $102,768150 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $138 | $64,987107 claims |
| NovartisEntresto | $197 | $55,37481 claims |
| Novo NordiskOzempic, Rybelsus | $692 | $52,38347 claims |
| MerckJanuvia | $196 | $48,24156 claims |
| Johnson & JohnsonXarelto | $214 | $37,16168 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $264 | $36,61833 claims |
| AbbVieLinzess, Restasis | $243 | $25,49344 claims |
| Lilly USA, LLCTrulicity | $428 | $21,11021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Saluda
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.